Adis Journals
ALBRIOZA_summary.pdf (590.06 kB)

Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval

Download (590.06 kB)
Version 3 2022-07-28, 22:42
Version 2 2022-07-28, 22:41
Version 1 2022-07-28, 22:38
online resource
posted on 2022-07-28, 22:42 authored by Young-A Heo



Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Young-A Heo is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable. 

Additional information about this Adis Drug Review can be found here



An oral, fixed-dose coformulation of sodium phenylbutyrate and ursodoxicoltaurine (ALBRIOZA™; hereafter denoted sodium phenylbutyrate/ursodoxicoltaurine) is being developed by Amylyx Pharmaceuticals for the treatment of neurodegenerative diseases. In June 2022, the coformulation received its first approval with conditions in Canada for the treatment of amyotrophic lateral sclerosis (ALS) in adults. The approval was based on results from the a multicenter, phase II CENTAUR trial, in which slowing of ALS progression was demonstrated with sodium phenylbutyrate/ursodoxicoltaurine relative to placebo. This article summarizes the milestones in the development of sodium phenylbutyrate/ursodoxicoltaurine leading to this first approval.

 © Springer Nature Switzerland AG 2022 


Usage metrics

    CNS Drugs



    Ref. manager